Biotechnology company developing portfolio of psychoactive compounds targeted for treatment of mental conditions and other disorders PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCMKTS: PSYBF) announced having initiated its first European pilot batch manufacturing of its biosynthetic formulation of psilocybin in partnership with Biose Industrie.
Biose Industrie is a certified manufacturer of bacteria-based and clinical commercial products. The company has over 70 years of experience in commercializing therapeutics developed and produced utilizing live bacterial strains.
PsiBio’s chief executive officer, Evan Levine, says this partnership with Biose is a strategic one t help the company expand its operations beyond North America.
“In our effort to expand our clinical development beyond North America, we are pleased to be working with Biose, a highly competent company operating under a Good Manufacturing Practices (GMP) certified facility located in Aurillac, France, for the manufacturing of our bacteria-based drug substance and drug products in the European Union (EU) for further pre-clinical and clinical scientific evaluation,” said the CEO.